Inventage Lab launches clinical trials for addiction treatment in Australia

South Korea's Inventage Lab, a developer of a drug delivery system platform, on Wednesday said it received approval from the Human Research Ethics Committee of Australia for a Phase 1 clinical trial for IVL3004, a long-acting injectable medicine for treating alcohol and drug addiction.

IVL3004 uses technology to release a certain concentration of drugs into the body for the target period and blocks dependence on alcohol and drugs from just one injection per month, the company said.

Through a Phase 1 clinical trial on 30 patients, the company will evaluate the safety of IVL3004.

Inventage Lab possesses technology in the development of long-lasting injectable medicine and LNP (lipid nanoparticle) platforms used in mRNA and gene therapy. It was listed on the over-the-counter stock market KOSDAQ in November last year.

Write to Jae-Young Han at jyhan@hankyung.com